Program
Ciliary Neurotrophic Factor
Also written as “NT-501”, “Ciliary neurotrophic factor (CNTF)” and “NT-501/revakinagene taroretcel-lwey”.
Its studies are mostly in Telangiectasis · Retinitis Pigmentosa · Eye Diseases · Usher Syndromes, led by Neurotech Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurotech Pharmaceuticals | 111 open or running | phase 4since Apr 29, 2025 | Mar 9, 2007 | Jan 15, 2032phase 4 · NCT06971939 |
Also a collaborator on its studies: the-emmes-company-llc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2007First studies: 3 phase 2 studiesFirst studyNCT00447993, NCT00447980, NCT00447954
- Mar 30, 2011Phase 1 study in Idiopathic Juxtafoveal Retinal TelangiectasiaNCT01327911 · 7 enrolled · United States
- Jan 19, 2012Phase 2 study in Retinitis PigmentosaNCT01530659 · 22 enrolled · United States
- Sep 19, 2013Phase 2 study in Macular Telangiectasia Type 2NCT01949324 · 67 enrolled · United States, Australia
- Mar 1, 2017Phase 2 study in MacTel (Macular Telangiectasia) Type 2NCT03071965 · 70 enrolled · United States, Australia
- Oct 3, 20172 phase 3 studiesNCT03319849, NCT03316300
- Jan 25, 2021Phase 2 study in Macular Telangiectasia Type 2NCT04729972 · 33 enrolled · United States, Australia
- Apr 29, 2025Phase 4 study in Macular Telangiectasia Type 2 (MacTel)NCT06971939 · 234 planned · United States, Australia
Ahead
- Jan 15, 2032Primary completion: phase 4 study in Macular Telangiectasia Type 2 (MacTel)NCT06971939
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06971939Macular Telangiectasia Type 2 (MacTel) · United States, Australia | 4 | Recruiting | Jan 15, 2032 | 234 |
| NCT04729972Macular Telangiectasia Type 2 · United States, Australia | 2 | Completed | Dec 8, 2022 | 33 |
| NCT03319849Macular Telangiectasia Type 2 · United States, Australia, Germany | 3 | Completed | Aug 31, 2022 | 119 |
| NCT03316300Macular Telangiectasia Type 2 (MacTel) · United States, Australia, France and more | 3 | Completed | Aug 31, 2022 | 120 |
| NCT03071965MacTel (Macular Telangiectasia) Type 2 · United States, Australia | 2 | Completed | May 11, 2021 | 70 |
| NCT01949324Macular Telangiectasia Type 2 · United States, Australia | 2 | Completed | Apr 14, 2017 | 67 |
| NCT01530659Retinitis Pigmentosa · United States | 2 | Completed | Jul 1, 2019 | 22 |
| NCT01327911Idiopathic Juxtafoveal Retinal Telangiectasia · United States | 1 | Completed | Sep 2016 | 7 |
| NCT00447993Retinitis Pigmentosa · United States | 2 | Completed | May 26, 2009 | 67 |
| NCT00447980Retinitis Pigmentosa · United States | 2 | Completed | Apr 19, 2010 | 73 |
| NCT00447954Eye Diseases · United States | 2 | Completed | May 11, 2009 | 53 |
How it is read
Names in the registry
- “NT-501”, 5 entries
- “Ciliary neurotrophic factor (CNTF)”, 2 entries
- “NT-501/revakinagene taroretcel-lwey”, 1 entry
- “High Dose NT-501 implant”, 1 entry
- “Low Dose NT-501 implant”, 1 entry
Conditions, from the studies’ own filings
- Telangiectasis, 6 studies
- Retinitis Pigmentosa, 2 studies
- Eye Diseases, 1 study
- Usher Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.